Sterilization has its advantages.

Through a unique, proprietary process DermaSpan™ Acellular Dermal Matrix is supplied sterile (SAL-10⁶). Histology studies have shown that Precision Dose Sterilization allows the graft to be sterilized while maintaining tissue integrity.¹

**Histology Studies¹**

These histology studies show no changes to the matrix, post sterilization:

![Histology Studies Images]

**Transmission Electron Micrographs (TEMs)¹**

TEMs presented the same results. There is a similar collagen structure between normal dermis and dermis treated with the patented gamma precision sterilization process. Ultimately, DermaSpan Acellular Dermal Matrix is preserved through processing.

![TEM Images]
Tensile strength is defined as the pulling force required to break a material standardized to its cross-sectional area. 

- 19.2 MPa
- Exceeded tensile strength of competitor ACD graft

Suture pull-out strength is defined as the force required to separate the suture from the graft material.

- Suture failed before graft (Excel 0.0 Green Braided Suture)
- 166.1 Newtons pull-out with stainless steel wire

**Feature** | **Benefit**
---|---
Acellular dermal matrix | One lab study has shown acellular dermal matrix leads to reduced chance of inflammatory response.\(^2\)
Allograft | Reduced risk of rejection as compared with xenograft.\(^3,4\)
Infiltrated by host tissue | Effective graft procedures.
High suture pull-out strength | Enhances tissue reinforcement.
Provided sterile | Unique, proprietary process, provides one of a few acellular dermal matrix products that is irradiated under validated sterilization process. Using sterile graft further reduces the risk of disease donor transmission.\(^5\)
Convenient delivery sizes | Three sizes to address surgeon's needs.
No special handling or storage requirements | Does not need to be refrigerated.
Easily reconstituted in the O.R. | Simply hydrate in normal saline for 5–10 minutes.

Meets all FDA, AATB and state regulatory requirements for testing and donor screening

---

[DermaSpan Acellular Dermal Matrix](#) is derived from allograft skin. DermaSpan Acellular Dermal Matrix is very carefully processed to offer biocompatibility as well as biomechanical strength in tendon coverage or reinforcement and wound coverage procedures. DermaSpan Acellular Dermal Matrix has the added advantage of being supplied sterile...unlike many other dermal allograft products.

**Ultimate Tensile Strength for Various Acellularized Dermis**\(^6,7\)

<table>
<thead>
<tr>
<th>Material</th>
<th>Tensile Strength (MPa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DermaSpan Acellular Dermal Matrix</td>
<td>19.3</td>
</tr>
<tr>
<td>DermaMatrix Non-Sterile</td>
<td>17.2</td>
</tr>
<tr>
<td>Allopatch HD Non-Sterile</td>
<td>16.7</td>
</tr>
<tr>
<td>DermalMatrix Processing Resins (VP &lt;71&gt; / 71 &lt;20)</td>
<td>14.8</td>
</tr>
</tbody>
</table>

**ACD Suture Pull-out Strength vs. Suture Break Strength**\(^6,7\)

<table>
<thead>
<tr>
<th>Material</th>
<th>Pull-out Strength (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DermaSpan Acellular Dermal Matrix Utilizing 1.8mm Stainless Steel Wire</td>
<td>166.1</td>
</tr>
<tr>
<td>Excel Size 0 Green Braided Suture (Polyester)</td>
<td>100</td>
</tr>
</tbody>
</table>

**Suture Pull-out Strength**\(^6\)

- Suture failed before graft (Excel 0.0 Green Braided Suture)
- 166.1 Newtons pull-out with stainless steel wire

**Tensile Strength**\(^6\)

- Tensile strength is defined as the pulling force required to break a material standardized to its cross-sectional area.
  - 19.2 MPa
  - Exceeded tensile strength of competitor ACD graft
### Ordering Information

<table>
<thead>
<tr>
<th>DermaSpan Acellular Dermal Matrix</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>92-1100505 5 x 5 cm (.8mm – 1.4mm thickness)</td>
<td>92-1100407 4 x 7 cm (.8mm – 1.4mm thickness)</td>
</tr>
<tr>
<td>92-1100407 4 x 7 cm</td>
<td>92-1100510 5 x 10 cm (.8mm – 1.4mm thickness)</td>
</tr>
</tbody>
</table>

The DermaSpan™ Acellular Dermal Matrix is available in multiple sizes and thicknesses. Selection for the appropriate product size is the responsibility of the surgeon based on the individual patient needs. Graft thickness and strength should be considered based on application.


7. As reported by competitors.

*Bench test results are not necessarily indicative of clinical performance.

All trademarks herein are the property of Biomet, Inc. or its subsidiaries unless otherwise indicated.

This material is intended for the sole use and benefit of the Biomet sales force and physicians. It is not to be redistributed, duplicated or disclosed without the express written consent of Biomet.

For product information, including indications, contraindications, warnings, precautions and potential adverse effects, see the package insert and Biomet's website.